公开(公告)号：US08846853B2

公开(公告)日：2014-09-30

申请号：US13511311

申请日：2011-11-03

Applicant: Hong Li ,  Quanxing Zhang ,  Wei Jiang ,  Wei Huang ,  Bingcai Pan

Inventor： Hong Li ,  Quanxing Zhang ,  Wei Jiang ,  Wei Huang ,  Bingcai Pan

IPC: C08G63/08 ,  A61K47/32 ,  C08G63/82

CPC classification number: C08G63/823 ,  A61K47/32 ,  C08G63/08

Abstract: A direct polycondensation method for medical biodegradable polylactic acid (PLA). The invention uses commercialized creatinine (a type of biomaterial organic guanidine compounds—the arginine metabolite creatinine in human body) as the catalyst and industrial lactic acid (mass content 85-90%, aqueous solution) as the monomer to synthesize the PLA in terms of second polycondensation without solvent. Instead of tin catalysts having cytotoxicity, the catalyst used in the invention has high biocompatibility and biosafety. The synthesized PLA does not contain any metal and other toxic components; therefore, it can be used as the carrier for targeting drugs and controlled release drugs. The green catalyst and green processing method (no solvent applied and no toxic products produced) are used to synthesize the green biodegradable PLA with high biosafety. The molecular weight distribution for all synthesized products is narrow and the molecular weight is controllable within 1.5-3.0×104.

Abstract translation: 医用可生物降解聚乳酸（PLA）的直接缩聚方法。 本发明使用商业化肌酐（一种生物材料有机胍化合物 - 人体中的精氨酸代谢物肌酸酐）作为催化剂，工业乳酸（质量含量85-90％，水溶液）作为单体合成PLA 第二次缩聚无溶剂。 代替具有细胞毒性的锡催化剂，本发明中使用的催化剂具有高生物相容性和生物安全性。 合成的PLA不含任何金属和其他有毒成分; 因此，它可以用作靶向药物和控释药物的载体。 使用绿色催化剂和绿色加工方法（无溶剂应用，无有毒产物生产）合成具有高生物安全性的绿色生物降解PLA。 所有合成产物的分子量分布窄，分子量可控1.5-3.0×104。

公开(公告)号：US20140214673A1

公开(公告)日：2014-07-31

申请号：US13996298

申请日：2011-12-21

Applicant: JIM S. Baca ,  Hong Li ,  Tobias M. Kohlenberg ,  David Stanasolovich ,  Mark H. Price

Inventor： JIM S. Baca ,  Hong Li ,  Tobias M. Kohlenberg ,  David Stanasolovich ,  Mark H. Price

IPC: G06Q20/40

CPC classification number: G06Q20/40145 ,  G06Q20/0855 ,  G06Q20/3278 ,  G06Q20/363 ,  G06Q20/4016 ,  H04B5/0031 ,  H04B5/0068

Abstract: Generally, this disclosure describes authentication using biometric data for mobile device e-commerce transactions. A method may include capturing a mobile device user's biometric data; comparing the captured biometric data to authorized user biometric data stored on the mobile device; and authenticating an e-commerce transaction if the captured biometric data corresponds to the authorized user biometric data stored on the mobile device.

Abstract translation: 通常，本公开描述了使用用于移动设备电子商务交易的生物特征数据的认证。 一种方法可以包括捕获移动设备用户的生物测定数据; 将所捕获的生物测定数据与存储在移动设备上的授权用户生物特征数据进行比较; 以及如果所捕获的生物测定数据对应于存储在移动设备上的授权用户生物特征数据，则认证电子商务交易。

公开(公告)号：US20140173089A1

公开(公告)日：2014-06-19

申请号：US13715387

申请日：2012-12-14

Applicant: Hong Li ,  John B. Vicente ,  Mark D. Yarvis ,  James R. Blakley

Inventor： Hong Li ,  John B. Vicente ,  Mark D. Yarvis ,  James R. Blakley

IPC: H04L12/26

CPC classification number: H04L67/1097 ,  H04L41/18 ,  H04L67/18 ,  H04L67/2852

Abstract: Technologies for monitoring data storage location for cloud data include a cloud monitoring server configured to communicate with one or more cloud customer computing devices and cloud service providers. The cloud monitoring server receives monitoring requests from the cloud customer computing devices and retrieves provider information from the cloud service providers. The cloud monitoring server compiles response data based on the monitoring requests and the provider information, and sends response data to the cloud customer computing devices. Cloud customer computing devices may send on-demand monitoring requests and/or continuous, policy-based monitoring requests. For policy-based monitoring, the cloud monitoring server continually monitors the provider information and provides response data when one or more conditions specified in the policy are satisfied. The cloud monitoring server may also make recommendations and provide feedback based on the monitoring requests or the provider information. Other embodiments are described and claimed.

Abstract translation: 用于监视云数据的数据存储位置的技术包括配置为与一个或多个云客户计算设备和云服务提供商进行通信的云监控服务器。 云监控服务器接收来自云客户计算设备的监控请求，并从云服务提供商检索提供商信息。 云监控服务器根据监控请求和提供者信息编辑响应数据，并将响应数据发送给云客户计算设备。 云客户计算设备可以发送按需监视请求和/或连续的基于策略的监视请求。 对于基于策略的监控，云监控服务器持续监控提供商信息，并在满足策略中指定的一个或多个条件时提供响应数据。 云监控服务器还可以根据监控请求或提供者信息提出建议并提供反馈。 描述和要求保护其他实施例。

公开(公告)号：US20140090066A1

公开(公告)日：2014-03-27

申请号：US13628219

申请日：2012-09-27

Applicant: Hong Li ,  Alan D. Ross ,  Rita H. Wouhaybi ,  Tobias M. Kohlenberg

Inventor： Hong Li ,  Alan D. Ross ,  Rita H. Wouhaybi ,  Tobias M. Kohlenberg

IPC: G06F21/00

CPC classification number: H04L63/1433 ,  G06F21/51 ,  H04L67/02

Abstract: Systems and methods may provide for detecting a browser request for web content. Additionally, interaction information associated with a plurality of sources may be determined in response to the browser request, and a risk profile may be generated based on the interaction. The risk profile may include at least a portion of the interaction information as well as recommended control actions to mitigate the identified risk. In one example, the risk profile is presented to a user associated with the browser request as well as to a security control module associated with the platform.

Abstract translation: 系统和方法可以提供用于检测对web内容的浏览器请求。 此外，可以响应于浏览器请求来确定与多个源相关联的交互信息，并且可以基于交互来生成风险简档。 风险简档可以包括交互信息的至少一部分以及推荐的控制动作以减轻所识别的风险。 在一个示例中，将风险简档呈现给与浏览器请求相关联的用户以及与该平台相关联的安全控制模块。

公开(公告)号：US20140006219A1

公开(公告)日：2014-01-02

申请号：US13538087

申请日：2012-06-29

Applicant: Rita H. Wouhaybi ,  Hong Li ,  Stanley Mo ,  Mubashir A. Mian ,  Tobias M. Kohlenberg

Inventor： Rita H. Wouhaybi ,  Hong Li ,  Stanley Mo ,  Mubashir A. Mian ,  Tobias M. Kohlenberg

IPC: G06Q30/06

CPC classification number: G06Q30/06 ,  G06Q20/3274 ,  G06Q30/0235 ,  G06Q30/0259 ,  G06Q30/0267 ,  G06Q30/08

Abstract: Systems and methods may provide for implementing a counteroffer generation service. In one example, the method may include detecting an inquiry relating to an item offered by a vendor, analyzing the inquiry to determine the item, generating a counteroffer relating to the item, generating counteroffer code including the counteroffer relating to the item, and conducting a transaction relating to the item utilizing the counteroffer code.

Abstract translation: 系统和方法可以提供用于实施反代理商生成服务。 在一个示例中，该方法可以包括检测与供应商提供的项目相关的查询，分析查询以确定该项目，生成与该项目有关的反驳进程，生成包括与该项目有关的反驳进程的反驳销代码，以及进行 使用反驳代码与该项目有关的交易。

公开(公告)号：US20130244858A1

公开(公告)日：2013-09-19

申请号：US13606493

申请日：2012-09-07

Applicant: Hong Li

Inventor： Hong Li

IPC: C03C13/00

CPC classification number: C03C3/095 ,  C03C3/087 ,  C03C3/112 ,  C03C3/118 ,  C03C13/00 ,  C03C13/001 ,  C03C13/06 ,  C03C2213/00

Abstract: Embodiments of the present invention relate to glass compositions, glass fibers formed from such compositions, and related products. In one embodiment, a glass composition comprises 58-62 weight percent SiO2, 14-17 weight percent Al2O3, 14-17.5 weight percent CaO, and 6-9 weight percent MgO, wherein the amount of Na2O is 0.09 weight percent or less.

公开(公告)号：US08526475B2

公开(公告)日：2013-09-03

申请号：US12851947

申请日：2010-08-06

Applicant: Hong Li ,  Sally Pucilowski ,  Joseph S. Hayden

Inventor： Hong Li ,  Sally Pucilowski ,  Joseph S. Hayden

IPC: H01S3/17

CPC classification number: H01S3/175 ,  C03C3/062 ,  C03C3/068 ,  C03C3/17 ,  C03C3/19 ,  C03C4/0071 ,  H01S3/1611 ,  H01S3/1618 ,  H01S3/2308

Abstract: Disclosed are the use of phosphate-based glasses as a solid state laser gain medium, in particular, the invention relates to broadening the emission bandwidth of rare earth ions used as lasing ions in a phosphate-based glass composition, where the broadening of the emission bandwidth is believed to be achieved by the hybridization of the glass network.

Abstract translation: 公开了使用磷酸盐基玻璃作为固态激光增益介质，特别地，本发明涉及在磷酸盐基玻璃组合物中使用作为激发离子的稀土离子的发射带宽扩大，其中放射增加 相信通过玻璃网络的杂交来实现带宽。

公开(公告)号：US20130122489A1

公开(公告)日：2013-05-16

申请号：US13615284

申请日：2012-09-13

Applicant: Brian STUPI ,  Hong Li ,  Weidong Wu ,  Megan N. Hersh ,  David Hertzog ,  Sidney E. Morris ,  Michael L. Metzker

Inventor： Brian STUPI ,  Hong Li ,  Weidong Wu ,  Megan N. Hersh ,  David Hertzog ,  Sidney E. Morris ,  Michael L. Metzker

IPC: C12Q1/68 ,  C07H19/10 ,  C07H19/14

CPC classification number: C12Q1/6869 ,  B01L3/5027 ,  B01L2300/0654 ,  B01L2300/168 ,  C07H19/073 ,  C07H19/10 ,  C07H19/14 ,  C07H19/173 ,  C07H19/20 ,  C12Q1/6874 ,  C12Q1/6883 ,  C12Q2525/117 ,  C12Q2600/156 ,  C12Q2600/16

Abstract: The present invention relates generally to 3′-OH unblocked nucleotides and nucleosides labeled and unlabeled with 5-methoxy-substituted nitrobenzyl-based photocleavable terminating groups for use in methods and systems related to DNA and RNA sequencing and analysis. These compounds may be used as reversible terminators as they exhibit fast nucleotide incorporation kinetics, single-base termination, high nucleotide selectivity, and rapid terminating group cleavage that results in a naturally occurring nucleotide.

Abstract translation: 本发明一般涉及用于与DNA和RNA测序和分析相关的方法和系统中使用的5-甲氧基取代的硝基苄基基可光切割终止基团的3'-OH未封闭核苷酸和核苷标记和未标记的核苷。 这些化合物可以用作可逆终止子，因为它们表现出快速的核苷酸掺入动力学，单碱基终止，高核苷酸选择性以及导致天然存在的核苷酸的快速终止基团切割。

公开(公告)号：US08440702B2

公开(公告)日：2013-05-14

申请号：US13073190

申请日：2011-03-28

Applicant: Amjad Ali ,  Zhijian Lu ,  Peter J. Sinclair ,  Yi-Heng Chen ,  Cameron J. Smith ,  Hong Li

Inventor： Amjad Ali ,  Zhijian Lu ,  Peter J. Sinclair ,  Yi-Heng Chen ,  Cameron J. Smith ,  Hong Li

IPC: A61K31/4166 ,  A61K31/44 ,  C07D413/10

CPC classification number: C07D263/20 ,  C07D263/24 ,  C07D413/04 ,  C07D413/10 ,  C07D417/10 ,  C07D417/14

Abstract: Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. The compounds have 3 cyclic groups connected by single bonds, as for example triphenyl, which are attached directly to the ring of formula I or attached at the position B.

Abstract translation: 具有式I结构的化合物，包括化合物的药学上可接受的盐，是CETP抑制剂，可用于升高HDL-胆固醇，降低LDL-胆固醇，以及用于治疗或预防动脉粥样硬化。 化合物具有通过单键连接的3个环状基团，例如三苯基，其直接连接到式I的环或连接在位置B.

公开(公告)号：US20130116400A1

公开(公告)日：2013-05-09

申请号：US13511311

申请日：2011-11-03

Applicant: Hong Li ,  Quanxing Zhang ,  Wei Jiang ,  Wei Huang ,  Bingcai Pan

Inventor： Hong Li ,  Quanxing Zhang ,  Wei Jiang ,  Wei Huang ,  Bingcai Pan

IPC: C08G63/06

CPC classification number: C08G63/823 ,  A61K47/32 ,  C08G63/08

Abstract: The present invention provides a direct polycondensation method for medical biodegradable polylactic acid (PLA) using creatinine catalyzed lactic acid. The invention uses commercialized creatinine (a type of biomaterial organic guanidine compounds—the arginine metabolite creatinine (CR) in human body) as the catalyst and industrial lactic acid (LA, mass content 85-90%, aqueous solution) as the monomer to synthesize the high biosafety of medical PLA in terms of second polycondensation without solvent (identity). Instead of tin catalysts having cytotoxicity, the catalyst used in the invention has high biocompatibility and biosafety. The synthesized PLA does not contain any metal and other toxic components; therefore, it can be used as the carrier for targeting drugs and controlled release drugs. In addition, the green catalyst and green processing method (no solvent applied and no toxic products produced) are used in the invention to synthesize the green biodegradable PLA with high biosafety. The polymerization reaction is simple and the raw materials required are low in costs, thus it is easy for industrialization. Further, the molecular weight distribution for all synthesized products is narrow and the molecular weight is controllable within 1.5-3.0×104.

Abstract translation: 本发明提供使用肌酸酐催化乳酸的医用可生物降解聚乳酸（PLA）的直接缩聚方法。 本发明使用商业化肌酐（一种生物材料有机胍化合物 - 人体中的精氨酸代谢物肌酸酐（CR））作为催化剂，工业乳酸（LA，质量含量85-90％，水溶液）作为单体合成 医用PLA的高生物安全性在无溶剂（身份）的第二缩聚方面。 代替具有细胞毒性的锡催化剂，本发明中使用的催化剂具有高生物相容性和生物安全性。 合成的PLA不含任何金属和其他有毒成分; 因此，它可以用作靶向药物和控释药物的载体。 此外，本发明中使用绿色催化剂和绿色加工方法（无溶剂施用，无有毒产物）合成具有高生物安全性的绿色可生物降解PLA。 聚合反应简单，所需原料成本低，易于工业化。 此外，所有合成产物的分子量分布窄，分子量可控制在1.5-3.0×104内。